Company intelligence / Profile preview

MyoKardia

South San Francisco, California, United Statesorpha.net ↗

Ownership: Public · MYOK
Development stage: Commercial

Overview

Completed Phase 3 clinical trial for mavacamten with positive results announced in May 2020. Was planning NDA submission to FDA in Q1 2021. Also had promising early results from Phase Ib/IIa trial for danicamtiv in DCM patients.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

mavacamten

Commercial

Indications: Obstructive hypertrophic cardiomyopathy, Non-obstructive hypertrophic cardiomyopathy

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $153M
Total revenue: $32.6M
Enterprise value: $234.3M

Beyond the preview

Go deeper on MyoKardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyoKardia.

Explore the full profile